Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Gross Profit (2018 - 2025)

UroGen Pharma's Gross Profit history spans 8 years, with the latest figure at $34.5 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 56.37% year-over-year to $34.5 million; the TTM value through Dec 2025 reached $97.3 million, up 19.41%, while the annual FY2025 figure was $97.3 million, 19.41% up from the prior year.
  • Gross Profit reached $34.5 million in Q4 2025 per URGN's latest filing, up from $24.2 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $34.5 million in Q4 2025 to a low of $6.6 million in Q1 2021.
  • Average Gross Profit over 5 years is $17.6 million, with a median of $17.5 million recorded in 2024.
  • Peak YoY movement for Gross Profit: soared 3481.79% in 2021, then grew 4.0% in 2024.
  • A 5-year view of Gross Profit shows it stood at $14.6 million in 2021, then increased by 8.53% to $15.8 million in 2022, then skyrocketed by 34.21% to $21.2 million in 2023, then grew by 4.0% to $22.1 million in 2024, then skyrocketed by 56.37% to $34.5 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Gross Profit are $34.5 million (Q4 2025), $24.2 million (Q3 2025), and $20.7 million (Q2 2025).